SCHEMBL3485196

SCHEMBL3485196

Nc1ccc(Oc2ccc3cn[nH]c3c2)c(Cl)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.58
MEN1 O00255 3/20 0.58
MAPT P10636 3/20 0.58
KMT2A Q03164 3/20 0.58
PKM P14618 1/20 0.58
HTT P42858 1/20 0.58
NOS1 P29475 2/20 0.46
DYRK1A Q13627 2/20 0.46
ALDH1A1 P00352 2/20 0.46
GAA P10253 2/20 0.46
ROCK2 O75116 1/20 0.46
HPGD P15428 1/20 0.46
RAB9A P51151 1/20 0.46
ROCK1 Q13464 1/20 0.46
HIF1A Q16665 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
MAOB P27338 2/20 0.41
PDE7A Q13946 1/20 0.40
FGFR1 P11362 2/20 0.40
METAP2 P50579 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8325177 0.89 ROCK1 (0.58) KDM4EMEN1MAPTKMT2APKM
SCHEMBL8325182 0.84 KDM4E (0.58) KDM4EMEN1MAPTKMT2APKM
SCHEMBL3483763 0.79 MAPT (0.63) KDM4EMEN1MAPTKMT2APKM
SCHEMBL3484782 0.78 MEN1 (0.47) MEN1MAPTKMT2AHTTPDE7A
SCHEMBL2881162 0.77 PDPK1 (0.44) KDM4EGAAROCK1PDE7AFGFR1
SCHEMBL177260 0.75 MAPT (1.00) KDM4EMEN1MAPTKMT2APKM
SCHEMBL29559746 0.75 MAPT (1.00) KDM4EMEN1MAPTKMT2APKM
SCHEMBL1913888 0.75 LMNA (0.62) MAPTHTTALDH1A1GAAHIF1A
Bromide SCHEMBL2933643 0.74 MAPT (0.96) KDM4EMEN1MAPTKMT2APKM
Hydrochloric Acid SCHEMBL3871258 0.74 MAPT (0.96) KDM4EMEN1MAPTKMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004238-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed
EP-2103620-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-09-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004238-A1 FUSED HETEROCYCLIC COMPOUND ERBB2, ROS1, FLT3 KDM4E 621/4885MEN1 2063/4885MAPT 4025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.